Amide-containing NR2B/NMDA receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 6, 2006, Pages 863-870

  McCauley, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glutamate; hERG; NMDA; NR2B antagonist

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMIDE; BENZIMIDAZOLE DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; DIHYDROQUINOLINONE; DOFETILIDE; ELIPRODIL; IFENPRODIL; IONOTROPIC RECEPTOR ANTAGONIST; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL HERG; PYRAZOLOPYRIMIDINE DERIVATIVE; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; TRAXOPRODIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG SELECTIVITY; DRUG STRUCTURE; HEART DISEASE; HUMAN; LOCOMOTION; MOTOR DYSFUNCTION; NONHUMAN; PAIN; UNSPECIFIED SIDE EFFECT;

EID: 33745463771     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.6.863     Document Type: Article

References (32)

1. MADDEN DF: The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. (2002) 3(2):91-101.
2. HOCKING G, COUSINS MJ: Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. (2003) 97(6):1730-1739.
3. LIPTON SA, CHEN H-SV: Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. (2004) 11(1):18-20.
4. FERRIS SH: Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. (2003) 4(12):2305-2313.
5. SUGIHARA H, MORIYOSHI K, ISHII T, MASU M, NAKANISHI S: Structures and properties of seven isoforms of NMDA receptor gene-rated by alternative splicing. Biochem. Biophys. Res. Commun. (1992) 185(3):826-832.
6. LOFTIS JM, JANOWSKY A: The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical applications. Pharmacol. Therapeutics (2003) 97(1):55-85.
7. CHATTERTON JE, AWOBULUYI M, PREMKUMAR LS et al.: Excitatory glycine receptor containing the NR3 family of NMDA receptor subunits. Nature (2002) 415(6873):793-798.
8. MONYER H, BURNASHEV N, LAURIE DJ, SAKMANN B, SEEBURG PH: Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 12(3):529-540.
9. WILLIAMS K: Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanism at recombinant heteromeric receptors. Mol. Pharmacol. (1993) 44(4):851-859.
10. BOYCE S, WYATT A, WEBB JK et al.: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology (1999) 38(5):611-623.
11. CHIZH BA, HEADLEY PM, TZSCHENTKE TM: NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci. (2001) 22(12):636-642.
12. PEDERSEN V, SCHMIDT WJ: The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs. Neurotoxicity Res. (2000) 2(2-3):179-204.
13. KEMP JA, MCKERNAN RM: NMDA receptor pathways as drug targets. Nature Neurosci. (2002) 5(Suppl.):1039-1042.
14. CHAZOT PL: The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. (2004) 11(3):389-396.
15. HYND MR, SCOTT HL, DODD PR: Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. (2004) 90(4):913-919.
16. ALBERCH J, CANALS JM, PÉREZ-NAVARRO E. Therapeutic strategies in Huntington's disease. Expert Opin. Ther. Patents (2003) 13(4):449-465.
17. KOHL BK, DANNHARDT G: The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. (2001) 8(11):1275-1289.
18. NAGY J: Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? Invest. Drugs J. (2004) 7(4):339-350.
19. CHENARD BL, MENNITI FS: Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. (1999) 5(5):381-404.
20. NIKAM SS, MELTZER LT. NR2B selective NMDA receptor antagonists. Curr. Pharm. Des. (2002) 8(10):845-855.
21. MCCAULEY JA. NR2B subtype-selective NMDA receptor antagonists: 2001-2004. Expert. Opin. Ther. Patents (2005) 15(4):389-407.
22. BORZA I, DOMÁNY G: NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr. Top. Med. Chem. (2006) 6(7):687-695.
23. LAYTON ME, KELLY MJ, RODZINAK KJ: Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr. Top. Med. Chem. (2006) 6(7):697-709.
24. CHENARD BL, BORDNER J, BUTLER TW et al.: (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. (1995) 38(16):3138-3145.
25. FISCHER G, MUTEL V, TRUBE G et al.: Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. (1997) 283(3):1285-1292.
26. MERCHANT RE, BULLOCK MR, CARMACK CA et al.: A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N.Y. Acad Sci. (1999) 890:42-50.
27. BULLOCK MR, MERCHANT RE, CARMACK CA et al.: An open-label study of CP- 101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. N.Y. Acad. Sci. (1999) 890:51-58.
28. SANG CN, WEAVER JJ, JINGA L, WOUDEN J, SALTARELLI MD: The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Program No. 814.9.2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003).
29. FARKAS S, HORVATH C, NAGY J et al.: RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Program No. 382.8.2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003).
30. BARTA-SZALAI G, BORZA I. BOZÓ E et al.: Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorq. Med. Chem. Lett. (2004) 14(15):3953-3956.
31. HÖFNER G, HOESL CE, PARSONS C, QUACK G, WANNER KT: NMDA-NR2B subtype selectivity of stereoisomeric 2-(1,2,3,4-tetrahydro-1-isoquinolyl)ethanol derivatives. Bioorg. Med. Chem. Lett. (2005) 15(9):2231-2234.
32. MCCAULEY JA, THEBERGE CR, ROMANO JJ et al.: NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem. (2004) 47(8):2089-2096.